부산대학교 도서관

Introduction: colon cancer is one of the most common forms of cancers. The incidence of colorectal cancer is 19.7 per 100.000 population according to Global Cancer Observatory (GLOBOCAN) worldwide in 2018. Microsatellite instability (MSI) is characterized by inactivation of the DNA repair system (deoxyribonucleic acid) and occurs in 5-15% of colorectal cancers. The presence of MSI is phenotypic evidence that mission repair systems (MMR) are not normally working. Aim: To determine the impact of microsatellite instability on the overall survival of patients with metastatic colorectal cancer. Materials and methods: The research is a retrospective, descriptive-analytical study was conducted at the Clinic of General and Abdominal Surgery, Clinic of Oncology and Clinical Pathology, Cytology and Human Genetic of the Clinical Center University of Sarajevo (CCUS) in the period from 2014 to 2020. A total of 101 patients were included in the study. The study included patients diagnosed with colorectal cancer (stages II and III according to AJCC - The American Joint Commission on Cancer) who underwent surgery and then received adjuvant chemotherapy. After adjuvant chemotherapy, patients were followed up to five years. Those patients whose distant metastasis was verified during the follow-up period were included in the study. The biomarkers of microsatellite instability (MSI) were determined in the patients included in the study, and for those who lacked MSI findings, additional/subsequent ones were performed in order to complete the findings. Overall survival (OS) calculation was done from the moment of metastasis until the end of the study, until the last written finding or death of the patient. Results: the average age was 59.69 (± 11,42). A comparison of the estimated OS (in months) by the Log Rank Mantel Cox test showed that there was no statistically significantly longer estimate of OS in the group of patients with MSS-marker compared to MSI-L cpf "OUK-H marker with 4" 0.527 and p=0.768. Conclu sion: predictive biomarker MSI has no direct effect on the overall survival of patients with metastatic CRC. MSI influences the choice of oncology therapy and the overall survival accordingly. [ABSTRACT FROM AUTHOR]